GlassScriptPhysician profile
Jason Price
NPI 1508025701
$63,728.59
in general payments reported to CMS, 2019-2025
22 companies · $20K in 2025
The $20K reported for 2025 was more than what 98% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,925 · 2020: $440 · 2021: $629 · 2022: $6,688 · 2023: $17K · 2024: $11K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $5,301 · Travel and Lodging: $4,311 · Consulting Fee: $3,600 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,641.03 |
| Food and Beverage | $5,301.17 |
| Travel and Lodging | $4,310.68 |
| Consulting Fee | $3,600.00 |
| Education | $194.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $47,588.74 | 2019-2025 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $7,204.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,775.32 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $1,560.51 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $830.39 | 2019-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $715.53 | 2019-2025 | |
| Amgen INC. | $513.29 | 2021-2025 | Tezspire |
| Harmony Biosciences LLC | $373.68 | 2023-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $243.61 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $198.94 | 2022-2024 | |
| Genentech USA, INC. | $190.17 | 2019-2020 | |
| Inspire Medical Systems, INC. | $148.14 | 2025 | Inspire |
| Jazz Pharmaceuticals INC. | $80.02 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $57.77 | 2021 | |
| Merck Sharp & Dohme LLC | $49.91 | 2019-2023 | Belsomra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $43.30 | 2025 | Azstarys |
| Covis Pharma Gmbh | $42.94 | 2021 | |
| Phadia US INC. | $41.44 | 2019-2024 | Immunocap |
| Alexion Pharmaceuticals, INC. | $22.49 | 2024 | Koselugo |
| Alk-Abello, INC | $19.50 | 2023 | Grastek, Odactra |
| Circassia INC. | $14.55 | 2020 | |
| Philips North America LLC | $13.51 | 2025 | Mcot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.